Free Trial Information
BioCentury | Sep 12, 2020
Management Tracks

New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

...Co. Ltd. (Tokyo:4502; NYSE:TAK) acquired, and Syndax Pharmaceuticals Inc. (NASDAQ:SNDX). Henk Schuring joined neurodegenerative disease company Prilenia Therapeutics B.V....
Read More
BioCentury | Jun 4, 2020
Emerging Company Profile

Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round

...disease progression by only a few months. Hayden has been serving as executive chairman of Prilenia Therapeutics B.V....
...consists of two tranches, with the second contingent on clinical progress, Hayden said. COMPANY PROFILE Prilenia Therapeutics B.V....
Read More
Items per page:
1 - 2 of 2
BioCentury | Sep 12, 2020
Management Tracks

New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

...Co. Ltd. (Tokyo:4502; NYSE:TAK) acquired, and Syndax Pharmaceuticals Inc. (NASDAQ:SNDX). Henk Schuring joined neurodegenerative disease company Prilenia Therapeutics B.V....
Read More
BioCentury | Jun 4, 2020
Emerging Company Profile

Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round

...disease progression by only a few months. Hayden has been serving as executive chairman of Prilenia Therapeutics B.V....
...consists of two tranches, with the second contingent on clinical progress, Hayden said. COMPANY PROFILE Prilenia Therapeutics B.V....
Read More
Items per page:
1 - 2 of 2